article thumbnail

FDA to Review and Possibly Ban Fluoride Supplements for Kids

Drugs.com

Food and Drug Administration (FDA) plans to review and possibly remove prescription fluoride supplements for children from the market.The FDA announced Tuesday that it intends to conduct the review by Oct. WEDNESDAY, May 14, 2025 The U.S.

FDA 191
article thumbnail

Novavax COVID Vaccine Moves Closer to Full FDA Approval

Drugs.com

Food and Drug Administration (FDA), the company said Wednesday.The update sent Novavaxs stock up more than 21% in early trading. FRIDAY, April 25, 2025 Novavaxs COVID-19 vaccine could soon receive full approval from the U.S. It also helped ease.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer

BioPharma Drive: Drug Pricing

Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.

FDA 363
article thumbnail

Duchenne approval exposes FDA rift over Sarepta gene therapy

BioPharma Drive: Drug Pricing

Peter Marks’ decision to override the objections of agency staff and broaden use of Elevidys could have a “lasting impact” on gene therapy as well as the FDA, one analyst wrote.

Therapies 337
article thumbnail

FDA Warns of Toxic Lead in Cinnamon Products

Drugs.com

The FDA urged folks to throw away and not buy the following brands of. WEDNESDAY, March 6, 2024 -- The U.S. Food and Drug Administration issued a health advisory Wednesday warning consumers that six brands of ground cinnamon are tainted with lead.

FDA 364
article thumbnail

Patrizia Cavazzoni, key FDA official, to leave agency

BioPharma Drive: Drug Pricing

The director of the FDA's main drug review office will exit on Jan. Her departure is one of several announced by high-ranking FDA leaders ahead of the coming administration change. 18, according to an email sent to staff.

FDA 292
article thumbnail

FDA makes end of Zepbound, Mounjaro shortage official

BioPharma Drive: Drug Pricing

Removal of Lilly’s in-demand drugs from the FDA’s shortage list ramps up pressure on the companies selling compounded versions.

FDA 301